Principal Component Analysis of CYP2C9 and CYP3A4 Probe Substrate/Inhibitor PanelsNATH, Abhinav; ATKINS, William.Drug metabolism and disposition. 2008, Vol 36, Num 11, pp 2151-2155, issn 0090-9556, 5 p.Article

Pharmacogenomics of coumarin anticoagulants : Are we underestimating the role of CYP2C9?SCHALEKAMP, Tom; MAITLAND -VAN DER ZEE, Anke-Hilse; DE BOER, Anthonius et al.Thrombosis and haemostasis. 2008, Vol 100, Num 2, pp 175-176, issn 0340-6245, 2 p.Article

Differential Genotype Dependent Inhibition of CYP2C9 in HumansKUMAR, Vikas; BRUNDAGE, Richard C; OETTING, William S et al.Drug metabolism and disposition. 2008, Vol 36, Num 7, pp 1242-1248, issn 0090-9556, 7 p.Article

Re-engineering of CYP2C9 to Probe Acid-Base Substrate SelectivityGUOYING TAI; DICKMANN, Leslie J; MATOVIC, Nicholas et al.Drug metabolism and disposition. 2008, Vol 36, Num 10, pp 1992-1997, issn 0090-9556, 6 p.Article

Mechanism of CYP2C9 Inhibition by Flavones and FlavonolsDAYONG SI; YING WANG; ZHOU, Yi-Han et al.Drug metabolism and disposition. 2009, Vol 37, Num 3, pp 629-634, issn 0090-9556, 6 p.Article

Association between the CYP2C9 polymorphism and the drug metabolism phenotypeTOPIC, Elizabeta; STEFANOVIC, Mario; SAMARDZIJA, Marina et al.Clinical chemistry and laboratory medicine. 2004, Vol 42, Num 1, pp 72-78, issn 1434-6621, 7 p.Article

CYP2C9 protein interactions with cytochrome b₅ : Effects on the coupling of catalysisLOCUSON, Charles W; WIENKERS, Larry C; JONES, Jeffrey P et al.Drug metabolism and disposition. 2007, Vol 35, Num 7, pp 1174-1181, issn 0090-9556, 8 p.Article

Detection of human CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissuesDELOZIER, Tracy C; KISSLING, Grace E; COULTER, Sherry J et al.Drug metabolism and disposition. 2007, Vol 35, Num 4, pp 682-688, issn 0090-9556, 7 p.Article

CYP2C9-CYP3A4 Protein-Protein Interactions: Role of the Hydrophobic N TerminusSUBRAMANIAN, Murali; TAM, Harrison; ZHENG, Helen et al.Drug metabolism and disposition. 2010, Vol 38, Num 6, pp 1003-1009, issn 0090-9556, 7 p.Article

Electrocatalytic Drug Metabolism by CYP2C9 Bonded to A Self-Assembled Monolayer-Modified ElectrodeMINGLI YANG; KABULSKI, Jarod L; WOLLENBERG, Lance et al.Drug metabolism and disposition. 2009, Vol 37, Num 4, pp 892-899, issn 0090-9556, 8 p.Article

Short communication: Characterization of the novel defective CYP2C9*24 alleleHERMAN, Darja; DOLZAN, Vita; INGELMAN-SUNDBERG, Magnus et al.Drug metabolism and disposition. 2007, Vol 35, Num 6, pp 831-834, issn 0090-9556, 4 p.Article

Genetic polymorphism of the CYP2C9 subfamily of 3 different races in warfarin maintenance doseGIN GIN GAN; PHIPPS, Maude Elvira; CHEE SENG KU et al.International journal of hematology. 2004, Vol 80, Num 3, pp 295-296, issn 0925-5710, 2 p.Article

Early overanticoagulation with acenocoumarol due to a genetic polymorphism of cytochrome p450 CYP2C9ANDRE-KERNEÏS, Elisabeth; LEROY-MATHERON, Catherine; GOUAULT-HEILMANN, Michèle et al.Blood coagulation & fibrinolysis. 2003, Vol 14, Num 8, pp 761-764, issn 0957-5235, 4 p.Article

Pharmacogenetics of oral anticoagulantsROJAS, Julio César; AGUILAR, Bernardo; RODRIGUEZ-MALDONADO, Emma et al.Blood coagulation & fibrinolysis. 2005, Vol 16, Num 6, pp 389-398, issn 0957-5235, 10 p.Article

CYP2D6-CYP2C9 Protein-Protein Interactions and Isoform-Selective Effects on Substrate Binding and CatalysisSUBRAMANIAN, Murali; LOW, Michael; LOCUSON, Charles W et al.Drug metabolism and disposition. 2009, Vol 37, Num 8, pp 1682-1689, issn 0090-9556, 8 p.Article

Relative Impact of Genotype and Enzyme Induction on the Metabolic Capacity of CYP2C9 in HealthyVolunteersVORMFELDE, S. V; BROCKMÖLLER, J; BAUER, S et al.Clinical pharmacology and therapeutics. 2009, Vol 86, Num 1, pp 54-61, issn 0009-9236, 8 p.Article

Several-fold increase in risk of overanticoagulation by CYP2C9 mutationsLINDH, Jonatan D; LUNDGREN, Stefan; HOLM, Lennart et al.Clinical pharmacology and therapeutics. 2005, Vol 78, Num 5, pp 540-550, issn 0009-9236, 11 p.Article

Warfarin and celecoxib interaction in the setting of cytochrome P450 (CYP2C9) polymorphism with bleeding complicationMALHI, H; ATAC, B; DALY, A. K et al.Postgraduate medical journal. 2004, Vol 80, Num 940, pp 107-109, issn 0032-5473, 3 p.Article

Pyrosequencing method for genotyping cytochrome P450 CYP2C8 and CYP2C9 enzymesHRUSKA, Matthew W; FRYE, Reginald F; LANGAEE, Taimour Y et al.Clinical chemistry (Baltimore, Md.). 2004, Vol 50, Num 12, pp 2392-2395, issn 0009-9147, 4 p.Article

Simultaneous Determination of Warfarin and 7-Hydroxywarfarin Enantiomers by High-Performance Liquid Chromatography With Ultraviolet DetectionMIURA, Masatomo; OKUYAMA, Shin; KATO, Shoutaro et al.Therapeutic drug monitoring. 2011, Vol 33, Num 1, pp 108-114, issn 0163-4356, 7 p.Article

Interindividual Variation in the Pharmacokinetics of Δ9-Tetrahydrocannabinol as Related to Genetic Polymorphisms in CYP2C9SACHSE-SEEBOTH, C; PFEIL, J; SEHRT, D et al.Clinical pharmacology and therapeutics. 2009, Vol 85, Num 3, pp 273-276, issn 0009-9236, 4 p.Article

Amiodarone analog-dependent effects on CYP2C9-mediated metabolism and kinetic profilesKUMAR, Vikas; LOCUSON, Chuck W; SHAM, Yuk Y et al.Drug metabolism and disposition. 2006, Vol 34, Num 10, pp 1688-1696, issn 0090-9556, 9 p.Article

Involvement of hepatocyte nuclear factor 4α in the different expression level between CYP2C9 and CYP2C19 in the human liverKAWASHIMA, Sachiyo; KOBAYASHI, Kaoru; TAKAMA, Kaori et al.Drug metabolism and disposition. 2006, Vol 34, Num 6, pp 1012-1018, issn 0090-9556, 7 p.Article

Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450 : a role for P-4502C9 in the etiology of (S)-warfarin-drug interactionsRETTIE, A. E; KORZEKWA, K. R; KUNZE, K. L et al.Chemical research in toxicology. 1992, Vol 5, Num 1, pp 54-59, issn 0893-228XArticle

Association of CYP2C9^*2 With Bosentan-Induced Liver InjuryMARKOVA, S. M; DE MARCO, T; KHOJASTEH, C et al.Clinical pharmacology and therapeutics. 2013, Vol 94, Num 6, pp 678-686, issn 0009-9236, 9 p.Article